Navigation Links
Long-Term Erythromycin Cut COPD Complications
Date:11/21/2008

But researchers remain cautious about future antibiotic resistance from widespread use

FRIDAY, Nov. 21 (HealthDay News) -- People with moderate to severe chronic obstructive pulmonary disease (COPD) may be able to reduce the frequency of exacerbations through a regular, low dose of a common antibiotic, a new report says.

The study, published in the first issue for December of the American Journal of Respiratory and Critical Care Medicine, found that twice-daily 250-milligram doses of erythromycin reduced exacerbations by as much as 35 percent.

The double-blind, placebo study found that more than twice as many COPD-related hospitalizations occurred among the placebo group, and that the median duration of the exacerbations was nine days in the erythromycin group, compared with 13 days in the placebo group.

"Our results did not allow us to determine a mechanism for these findings. However, based on in-vitro studies, we suspect that the mechanism is likely to involve the anti-inflammatory properties of erythromycin," study lead author Terence A.R. Seemungal, of the Department of Clinical Medical Sciences at the University of the West Indies, said in an American Thoracic Society news release.

The news is encouraging, following a recent report from the U.S. Centers for Disease Control and Prevention that detailed the rising number of deaths related to COPD.

Seemungal did remain cautious about the findings, noting the threat of future antibiotic resistance resulting from widespread use of erythromycin. Also, not all the study patients received guideline-recommended therapy, such as inhaled corticosteroids or inhaled long-acting bronchodilators, which also have been shown to decrease exacerbation frequency. The degree of added benefit of erythromycin over and above standard therapy will require further study, he said.

"Observations that any intervention might decrease the frequency and severity of acute exacerbations in COPD present considerable public health implications," Dr. John Heffner, past president of the American Thoracic Society, said in the news release. "Exacerbations occur about once a year among patients with moderate to severe COPD and account for more than $30 billion dollars in direct and indirect costs annually in the United States alone."

"Many patients with advanced COPD receive highly potent, extended spectrum antibiotics during acute exacerbations,". "The relative risks of breeding resistance with a long-term preventative use of erythromycin versus more frequent short-term dosing of highly potent antibiotics for acute exacerbations require careful analysis. If future studies demonstrate similar efficacy of prolonged erythromycin therapy, especially if patients are already receiving inhaled steroids and long-acting bronchodilators, the benefits likely will outweigh the risks."

According to the U.S. National Institutes of Health, COPD is a progressive disease that makes it hard to breathe. It can cause coughing that produces large amounts of mucus, wheezing, shortness of breath, chest tightness, and other symptoms. Cigarette smoking is the leading cause of COPD.

More information

The U.S. National Heart, Lung, and Blood Institute has more about chronic obstructive pulmonary disease.



-- Kevin McKeever



SOURCE: American Thoracic Society, news release, Nov. 21, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Smoking may strongly increase long-term risk of eye disease
2. Long-Term Fatigue Plagues Cancer Survivors
3. Dont Ignore Tough or Long-Term Stomach Pain
4. Shaking may cause brain damage and serious long-term effects to infants
5. Sexual function affected by stem cell transplant according to long-term study
6. Smoking can harm the long-term effects of some oral surgery procedures
7. Childhood Obesity Epidemic a Long-Term Challenge
8. Conseco to Host Follow-Up Long-Term Care Conference Call
9. New Report Finds Information Technology Essential But Not Sufficient in Long-Term Care
10. No Link Between Amateur Boxing, Long-Term Brain Damage
11. No strong evidence linking amateur boxing with long-term brain injury
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Long-Term  Erythromycin Cut COPD Complications 
(Date:7/21/2017)... ... July 21, 2017 , ... ... students improve their chances of acceptance to a residency in a United States ... earned degrees outside the U.S. , According to data released by the ECFMG®, ...
(Date:7/21/2017)... ... July 21, 2017 , ... West Dermatology is pleased ... Vu, PA-C. Beginning July 17, 2017, Ms. Vu will join West Dermatology’s large network ... experience in dermatology, skin cancer , and more. She graduated from the University ...
(Date:7/21/2017)... ... July 21, 2017 , ... How physicians and ... the rise, say researchers presenting their work at the American Orthopaedic Society ... combination of evaluating the patterns of change in concussion symptom presentation, diagnostic tools ...
(Date:7/20/2017)... ... July 20, 2017 , ... Acute myeloid leukemia (AML) is ... rapidly without treatment. Newly diagnosed patients face intense chemotherapy regimens and a stem ... With such a challenging diagnosis that requires immediate action, patients and caregivers ...
(Date:7/20/2017)... ... ... For individuals with extended hospital stays or who are residents of nursing ... specially designed to accommodate patients with a wide range of ailments or special needs, ... has invented the patent-pending PORTABLE ARM REST, a specially designed armrest that features many ...
Breaking Medicine News(10 mins):
(Date:7/12/2017)... and Company (NYSE: LLY ) has entered into ... litigation in the U.S. District Court for the Eastern District ... (tadalafil) unit dose patent. This patent was previously set ... agreement, Cialis exclusivity is now expected to end at the ... patent for Cialis is valid and infringed by companies seeking ...
(Date:7/11/2017)... 11, 2017  The global market for liquid biopsy ... $394.1 million in 2016.  Although in early stages, the ... in particular as a result of the gradual shift ... recent introduction of a significant number of new liquid ... of tumor biomarkers to guide treatment decisions. ...
(Date:7/11/2017)... July 11, 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... pharmaceutical company focused on the development of oral drug ... Drug Administration (FDA) has agreed to schedule an End-of-Phase ... IIb trial of its oral insulin capsule ORMD-0801 in ... trial met primary and secondary endpoints by indicating a ...
Breaking Medicine Technology: